Julie Hambleton is on the board of IGM Biosciences, Inc., Erasca, Inc., Springworks Therapeutics, Inc. and Gennao Bio, Inc.

She previously held the position of President, Chief Executive Officer & Director at Arch Oncology, Inc., Chief Medical Officer, SVP & Head-Development at IDEAYA Biosciences, Inc., Vice President & Head-US Medical at Bristol Myers Squibb Co., Vice President-Clinical Development at Clovis Oncology, Inc., Chief Medical Officer & Executive Vice President at Five Prime Therapeutics, Inc., Medical Director-Global Clinical Development at Genentech, Inc. and Associate Professor at The University of California, San Francisco.

She received an undergraduate degree from Duke University and a doctorate from Case Western Reserve University School of Medicine.